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Abstract
According to current World Health Organization (WHO) updates, the COVID-19 pandemic has spread all over the globe,
affecting 216 countries, and has caused 8,860,331 confirmed
cases and 465,740 deaths as of June 24, 2020. Many countries cannot afford nucleic acid tests to confirm COVID-19 infection; as a result, people cannot know the COVID-19 status
of the people living around them. The use of dexamethasone

in COVID-19 hospitalized patients for up to 10 days lowered
28-day mortality compared to patients receiving standard of
care plus mechanical ventilation at randomization (by 12.3
age-adjusted percentage points, approximately one-third of
proportional reduction) and patients receiving oxygen without
invasive mechanical ventilation (by 4.1 age-adjusted percentage points, approximately one-fifth of proportional reduction).

Introduction

June 22, 2020.[1] The government has taken substantial
measurements and Quarantine has been established in
major emergency centers, but still, the cases of COVID19 have increased very rapidly.

According to World Health Organization (WHO) current updates, the COVID-19 pandemic has spread
all over the globe affecting 216 countries and caused
8,860,331 confirmed cases and 465,740 deaths last followed by 24 June 2020.[1] Many countries cannot afford
the nucleic acid tests to confirm COVID-19 infected patients; as a result, people cannot know the COVID-19
status of the people living around them.
Since the last century with the advent of technology
and advancement, it was barely rare to see such pandemic. It has been a new, unique, and challenging condition for the whole world including Science. America being the technology king and one of the developed countries had worst affected by this virus. Currently, the registered confirmed cases in America are
2,241,178 with 119,453 deaths. Brazil has been affected
as the second most country with registered cases of
1,067,579 with 49,976 deaths. Russian Federation is
the third country with registered cases 592,280 with
8,206 deaths.[1] The overall global count for the cases is
8,860,331 with 465,740 deaths (Figure 1). Interestingly
all these conditions are developed and highly technologically advanced countries. Pakistan is also affected
very badly by the current virus. The first case was
reported on 26 February 2020 and it is increasing exponentially and now the active number of cases are
181,088 and 3,590 deaths were reported to WHO on
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Methods
The COVID-19 infection spread from person to person; therefore, the affected COVID-19 patients are kept
in isolation where they are given treatments. Currently, no specific antiviral drugs or vaccines are available for treating COVID-19. The COVID-19 patients are
given empiric therapy which includes HIV protease inhibitors and also broad-spectrum antiviral drugs like
nucleoside analog that could attenuate the infection until the availability of specific antiviral drugs.[2]
The WHO also recommends convalescent plasma for
the treatment of COVID-19 patients. But recently, the
promising results of the clinical trials of dexamethasone in the United Kingdom were welcomed by WHO.
The dexamethasone, a corticosteroid, can be life-saving
for seriously ill COVID-19 patients.[3] The preliminary
reports shared with the WHO showed that dexamethasone reduced mortality by one third in patients on ventilators, and by one fifth in patients requiring only oxygen. The effectiveness of this drug was only observed
in critically ill COVID-19 patients and was not reported
in patients with milder symptoms of the disease. The
WHO Director-General, Dr. Tedros Adhanom Ghe1
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Figure 1. Current status of COVID-19 across the globe.

breyesus has said that it is the first drug to have reduced mortality in patients in COVID-19 patients on
ventilators or requiring oxygen.[3]

Results
Dexamethasone, steroid, that reduces inflammation
(the main cause of death in COVID-19 patients, lungs
swells during the fight with the virus) has been used
in different conditions like certain cancers and inflammatory disorders since the 1960s. It has been included
in the WHO Model List of Essential Medicines, in many
formulations since 1977, and is currently affordable and
off-patent in most of the countries.[3]
Advantages of dexamethasone
It has been shown that dexamethasone saves lives: a
clinical trial over 4 weeks in the Oxford University observed that it reduced the mortality rate by 35% in
COVID-19 patients on ventilators and 20% in those
who needed oxygen only. Studies have shown that
this drug would prevent the death of 1 patient for every 8 COVID-19 patients on ventilators and 1 for every 25 COVID-19 patients who need supplemental oxygen only. Another key advantage of this drug is that it
is cheap and easily available in most of the countries
worldwide.
Side effects of dexamethasone
Dexamethasone is an only useful drug for treating
critically ill COVID-19 patients, but there are some
side effects of using steroids, including water retention, weight gain, high blood pressure, sleep problems,
mood changes, and raise the blood sugar level in diabetic patients. However, some researchers have also
reported that the mortality rate was high during a clin-
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ical trial: the mortality rate in COVID-19 patients on
ventilators and oxygen alone were 41% and 25% respectively. This mortality rate seems higher than in the
United States, where recently mortality rate of 12% was
found, although it was only 2 weeks versus 4 in the
United Kingdom study, said Dr. Peter Bach a health
policy expert at Memorial Sloan-Kettering Cancer Centre in New York.

Discussion
The preliminary results of a study conducted by Group
(Table 1) showed that the use of dexamethasone in
COVID-19 hospitalized patients for up to 10 days lower
28-day mortality as compared to the patients taking
usual care and also receiving mechanical ventilation at
randomization (by age-adjusted percentage points 12.3,
approximately one third of proportional reduction) and
those patients receiving oxygen without invasive mechanical ventilation (by age-adjusted percentage points
4.1, approximately one fifth of proportional reduction).
However, they did not note any evidence of dexamethasone benefits in those patients that were not receiving any respiratory support at randomization, and
the findings were similar with the possible harm in
this subgroup. In all those patients of COVID-19 having common inflammatory lung damage and they were
treated for more than 07 days after onset of symptoms,
the use of dexamethasone was also found to be effective.[4]
Recently, another trial was conducted in which the
patients having acute respiratory distress syndrome
and also receiving mechanical ventilation, the mortality at 60 days was 15% lower in the dexamethasone
group as compared to the other group receiving usual
care.[5] These findings are also parallel to the results of
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Table 1. Dexamethasone in COVID-19 Hospitalized Patients.[4]

Primary outcome
Mortality at 28 days
Secondary outcomes
Discharged within 28 days from the hospital
Invasive mechanical ventilation
Death or invasive mechanical ventilation
Deaths

Standard of care
(n=2,104)

Dexamethasone
(n=2,104)

Risk/rate ratio
[95% CI]

1,110/4,321 (25.7)

482/2,104 (22.9)

0.83 [0.75–0.93]

2,745/4,321 (63.5)
285/3,638 (7.8)
994/3,638 (27.3)
827/3,638 (22.7)

1,413/2,104 (67.2)
102/1,780 (5.7)
456/1,780 (25.6)
387/1,780 (21.7)

1.10 [1.03–1.17]
0.77 [0.62–0.95]
0.92 [0.84–1.01]
0.93 [0.84–1.03]

Abbreviations: CI, confidence interval.
∗ Frequency/total (%).

Group.[4]
These trials provide evidence that all COVID-19 patients that receiving respiratory support, when treated
with a dose of 6 mg once daily at least for up to 10 days
with dexamethasone reduces 28-day mortality. They
did not found any benefit and also the harm possibility among all those patients who did not need any kind
of respiratory support.[4]

Received: July 8, 2020
Accepted: September 3, 2020

So, dexamethasone is now present on the essential
medicines list of WHO and easily available throughout
the world at minimum price.
The National Institutes of Health (NIH) in the USA and
the chief medical officers of U.K issued and updated
guidelines to recommend the use of glucocorticoids in
COVID-19 hospitalized patients.[4]
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